Celine Weber is Managing Associate in the Healthcare and Life Sciences Team. She completed a master’s degree in life sciences law in 2012 and started working in the field in 2013. She is specialized in the regulation of the pharmaceutical and the medtech industry, including the regulation on marketing authorizations and licenses, market access and reimbursement, advertising, product classification, anti-bribery legislation and clinical trials. She also regularly advises on regulatory questions surrounding foodstuffs (including supplements and FSMP), cosmetics and genetic testing.

She has extensive experience representing clients in court proceedings and before administrative authorities in life sciences matters. She also serves as person responsible for pharmaceutical advertising. Furthermore, she is a lecturer for the Certificate of Advanced Studies (CAS) in Rare Diseases at the University of Zurich.

Celine Weber is Co-Founder and Board Member of W@LifeSciencesCH. She regularly writes about and gives talks on life sciences law, e.g. on Swiss advertising or anti-bribery legislation.

She studied at the universities of Zurich, Geneva, Paris X Nanterre and New South Wales in Sydney. Before joining Walder Wyss, Celine Weber worked as a court clerk at the District Court in Meilen and as a trainee lawyer at a major law firm in Zurich. Furthermore, she worked as an in-house counsel at an international pharmaceutical company.

Celine Weber speaks German, English, French and Norwegian. She has been admitted to the Bar Association of the Canton of Zurich and is authorized to conduct legal proceedings throughout Switzerland.

Stepping into the future: A closer look at the third revision oft the Therapeutic Products Act (TPA / HMG)

Swiss pharmaceutical reimbursement and pricing: Ordinance Law Changes (KVV/KLV) as of January 2024: Today's Decision by the Swiss Federal Council (Bundesrat)

Triennial review of medicines’ SL prices: Lessons learned from appeals won against the FOPH

QR codes for medicines – new guidance

Food for Special Medical Purposes (FSMP): New specific CJEU requirements

Genetic Testing – An Overview of the New Provisions

Pharmaceutical Advertising 2022 - Switzerland

Das Life Sciences Law Review, Kapitel 24 – Schweiz

Pharmawerbung – Schweiz

The Life Sciences Law Review Chapter 28 - Switzerland

Lebensmittel- und Gebrauchsgegenständerecht

Die Kennzeichnung und Anpreisung von Lebensmitteln und Gebrauchsgegenständen

Handbook on Foodstuffs and Utility Articles law

Life Science Law Update

Life Science Law Update

Life Science Law Update

Life Science Law Update

Mehr Transparenz bei der Swissmedic

Life Science Law Update

The Life Sciences Law Review - Chapter 29: Switzerland

Pharmawerbung – Schweiz

Die E-Zigarette im schweizerischen Recht

Nikotinhaltige E-Zigaretten im schweizerischen Recht

Zur Qualifikation von «Frequenzpflastern» als Medizinprodukte